"I think we may even see a tweak in what the phase
Post# of 72440
It is not frequent but not unknown for the FDA to accept two P2 trials with outstanding results as the basis for an NDA. If Brilacidin is classified as an NME then the precedent for 2 P2 trials may not be as strong.
Awaiting more data here, also.